Current Collaborations and Initiatives
Lupus Therapeutics has been involved in some of the most important breakthroughs in lupus research and is helping to guide future breakthroughs.
Current/Ongoing Partner Studies
Study Name: Abbvie SELECT-SLE
Phase 3, SLE
Up to 20 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: Biogen TOPAZ-1
Phase 3, SLE
10 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: Biogen TOPAZ-2
Phase 3, SLE
8 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: BMS POETYK-1 SLE
Phase 3, SLE
15 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: BMS POETYK-2 SLE
Phase 3, SLE
13 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: Novartis SIRIUS SLE 1
Phase 3, SLE
Up to 11 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: Novartis SIRIUS SLE 2
Phase 3, SLE
4 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: UCB PHOENYCS GO
Phase 3, SLE
27 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: Novartis SIRIUS LN
Phase 3, LN
Up to 15 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: VeraTx COMPASS
Phase 3, LN
13 LuCIN sites (U.S. and Canada)
On Hold
Study Name: Biogen AMETHYST
Phase 2, 3, CLE
16 LuCIN sites (U.S. and Canada)
Recruiting
Study Name: VIBRANT
Phase 2, LN
15 LuCIN sites (U.S. and Canada)
Active, Not Recruting
Study Name: Gilead COSMIC
Phase 2, CLE
7 LuCIN sites (U.S. and Canada)
Recruiting
Current Collaborations
Artiva Allogeneic NK
Allogeneic, Non-genetically Modified Natural Killer Cells
AB-101-03 Phase 1
Advisory/Clinical Services
BMS CAR-T
CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells
CA061-1001 Phase 1
Cabaletta Bio CAR T Therapy
CABA-201, An Autologous CD19-Chimeric Antigen Receptor T cells (CAR T) Therapy, SLE and LN
CAB-201-001 Phase 1/2 Trial
Advisory/Clinical Services
Caribou Biosciences
Advisory Services
Century Therapeutics CAR NK Cell Therapy
CNTY-101: Allogeneic iPSC-derived CD19-CAR NK Cells
CALiPSO-1, Phase 1, Moderate to Severe SLE
Clinical Services
EMD Serono M5049 WILLOW
Toll-like receptor (TLR) 7/8 Inhibitor
Phase 2, SLE and/or CLE
Fate Stem Cell Therapy
Induced Pluripotent Stem Cell (iPSC)
Advisory/Clinical Services
iCell Gene Therapeutics
Advisory Services
Nkarta CAR NK
Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK)
NKX019-102 Phase 1
Advisory/Clinical Services
Ventus c-GAS
cGAS/STING Inhibitor
Advisory Services
Historical/Completed Studies
Study Name: RIFLE
Phase 4, SLE
21 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: Janssen LOTUS
Phase 3, SLE
27 LuCIN sites (U.S. and Canada)
Terminated
Study Name: BMS Paisley SLE
Phase 2, SLE
21 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: AMG570
Phase 2, SLE
16 LuCIN sites (U.S. and Canada)
Terminated
Study Name: AMG592
Phase 2b, SLE
10 LuCIN sites (U.S. and Canada)
Terminated
Study Name: Celgene CC-220
Phase 2, SLE
22 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: EMD Serono M2591
Phase 2, SLE
8 LuCIN sites (U.S. and Canada)
Terminated
Study Name: Lilly BT01
Phase 2, SLE
4 LuCIN sites (U.S. and Canada)
Terminated
Study Name: Lilly ISLAND SLE (KFAJ)
Phase 2, SLE
15 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: VIB7734 RECAST SLE
Phase 2, SLE
7 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: Janssen Orchid
Phase 2, LN
6 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: BMS Paisley LN
Phase 2, LN
18 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: TAK-079
Phase 1b, SLE
10 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: Aker-ORKIDS
Phase NA, SLE
22 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: DIVINE
Phase NA, LN
7 LuCIN sites (U.S. and Canada)
Enrollment Ended
Study Name: VALUE
Phase NA, SLE
10 LuCIN sites (U.S. and Canada)
Enrollment Ended